Collegium Pharmaceutical (NASDAQ:COLL) has been given a $33.00 price objective by equities researchers at Piper Jaffray Companies in a research report issued to clients and investors on Monday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ price target would suggest a potential upside of 35.41% from the company’s current price.
A number of other research analysts have also issued reports on COLL. Needham & Company LLC boosted their price target on shares of Collegium Pharmaceutical from $28.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Janney Montgomery Scott set a $26.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a report on Tuesday, February 6th. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, January 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of Collegium Pharmaceutical in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. Collegium Pharmaceutical has a consensus rating of “Buy” and a consensus price target of $27.17.
Collegium Pharmaceutical (COLL) opened at $24.37 on Monday. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $26.77. The stock has a market cap of $793.54 and a PE ratio of -8.21.
In other Collegium Pharmaceutical news, CTO Alison B. Fleming sold 4,029 shares of the company’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $17.00, for a total value of $68,493.00. Following the sale, the chief technology officer now owns 28,513 shares of the company’s stock, valued at $484,721. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alison B. Fleming sold 4,601 shares of the company’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $17.25, for a total transaction of $79,367.25. Following the completion of the sale, the insider now directly owns 28,513 shares in the company, valued at approximately $491,849.25. The disclosure for this sale can be found here. Insiders sold 1,055,558 shares of company stock worth $18,570,177 in the last ninety days. Insiders own 25.76% of the company’s stock.
Large investors have recently bought and sold shares of the company. Voya Investment Management LLC acquired a new position in shares of Collegium Pharmaceutical in the second quarter valued at approximately $125,000. Benjamin F. Edwards & Company Inc. raised its position in shares of Collegium Pharmaceutical by 87.5% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock valued at $138,000 after buying an additional 3,500 shares during the last quarter. Nationwide Fund Advisors raised its position in shares of Collegium Pharmaceutical by 27.8% in the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after buying an additional 2,802 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $176,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Collegium Pharmaceutical in the third quarter valued at approximately $192,000. 82.40% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Collegium Pharmaceutical (COLL) PT Set at $33.00 by Piper Jaffray Companies” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/14/collegium-pharmaceutical-coll-pt-set-at-33-00-by-piper-jaffray-companies.html.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.